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Abstract
Objective: Endothelial dysfunction and microvascular damage play a crurical role in the pathogenesis of erectile
dysfunction (ED). Insulin-like growth factor-1 (IGF-1) is one of the growth factors that have a wide range of biologic
effects. IGF-1 is an important mediator of cell growth, differentiation and transformation in various tissues. The
purpose of the current study was to determine the association between IGF-1 levels and ED.
Materials and methods: All men were evaluated for ED and divided into two groups: 80 patients suffering from
ED for > 1 year and 80 subjects without ED were enrolled as a control group in this study. Diagnosis of ED was
based on the International Index of Erectile Function Score-5. IGF-1 levels were measured in serum by an
automated chemiluminescence immunoassay. The relationship between IGF-1 levels and ED scores in patients was
statistically evaluated.
Results: The mean age of patients in ED group was 60.4 ± 11.3 years and 55.4 ± 9.6 in control group. The plasma
IGF-1 levels were significantly lower in ED than in control group (96.5 ± 38.3 and 132.5 ± 53.3 ng/ mL, respectively,
P < 0.001). The IGF-1 levels were positively correlated with ED score (r = 0.623, P < 0.01).
Conclusion: In this study serum IGF-1 levels were found to be associated with endothelial dysfunction that predicts
ED. Serum IGF-1 level appears to be a specific predictor of ED, and it might be used in early prediction of ED in
male population.
Keywords: Endothelial dysfunction, Erectile dysfunction, Insulin-like growth factor-1, International Index of Erectile
Function Score-5
Résumé
Objectifs: La dysfonction endothéliale et les altérations vasculaires jouent un rôle crucial dans la pathogenèse de la
dysfonction érectile (DE). L’Insulin-like Growth Factor-1 (IGF-1) est l’un des facteurs de croissance qui ont un vaste
champ d’effets biologiques. IGF-1 est un médiateur important de la croissance, différentiation et transformation
cellulaires dans différents tissus. Le but de la présente étude était de rechercher une association entre les taux
d’IGF-1 et la dysfonction érectile.
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Matériel et Méthodes: La dysfonction érectile a été évaluée chez tous les hommes, constitués en 2 groupes : 80
patients souffrant de DE depuis plus d’un an, et 80 sujets sans DE recrutés comme groupe témoin dans l’étude. Le
diagnostic de DE était basé sur le score 5 de l’Index International de la Fonction Erectile. Les taux d’IGF-1 ont été
mesurés par immunodosage automatisé par chemiluminescence. La relation entre les taux d’IGF-1 et le score de la
DE a été statistiquement évaluée.
Résultats: L’âge moyen des patients du groupe DE était de 60.4±11.3 ans et de 55.4±9.6 dans le groupe témoin.
Les taux plasmatiques d’IGF-1 étaient significativement plus bas dans le groupe DE que chez les témoins
(respectivement 96.5±38.3 et 132.5±53.3 ng/mL, P < 0.001). Les taux d’IGF-1 étaient positivement corrélés au score
de la DE (r = 0.623, P < 0.01).
Conclusions: Nos résultats indiquent que les taux sériques d’IGF-1 sont associés à une dysfonction endothéliale qui
prédit la DE. L’IGF-1 sérique apparaît être un prédicteur spécifique de la DE, et il pourrait être utilisé pour une
prédiction précoce de la DE dans la population masculine.
Mots-clés: Dysfonction endothéliale, Dysfonction érectile, Insulin-like Growth Factor-1, IIEF-5
Background
Erectile dysfunction (ED) is defined as the recurrent or
consistent inability to obtain and maintain a penile
erection sufficient for satisfactory sexual performance,
it represents a common public health problem that
significantly impairs the quality of life and psycho-
logical well-being of the patient and his partner [1].
The incidence and the severity of ED increase with
age, reaching 20–40 % in men 60–69 yr of age and
50–100 % in men in their 70s and 80s, depending on
the differing definitions of ED in various studies [2].
Recent data demonstrate that ED is associated with
impaired endothelial-dependent flow-mediated dilatation
(FMD), suggesting that ED is associated with endothelial
dysfunction [3]. The etiology of ED is usually multifactor-
ial, with vascular, aging, hormonal, neurologic, and psy-
chological factors playing roles [4]. The common risk
factors, diabetes mellitus, hypertension, obesity, dyslipid-
emia, smoking and sedentary lifestyle, for endothelial
dysfunction and atherosclerosis have been frequently
found in patients with ED [5].
Insulin-like growth factor (IGF)-1, a peptide hormone
that is structurally related to insulin and synthesized
by almost all tissues, is an important mediator of cell
growth, differentiation and transformation in various
tissues [6]. IGF-1 is a potent mitogen and antiapopto-
tic factor for cell types and exerts all of its known
physiologic effects by binding to the IGF receptor
(IGF-1R) [7]. IGF binding activates IGF-1R, which in
turn phosphorylates phosphatidylinositol 3-kinase (PI-
3K) and Ras ⁄ Raf ⁄ mitogen-activated protein kinase
(MAPK). Ras ⁄ Raf ⁄ MAPK and PI-3K play important
roles in IGF1R- induced cellular proliferation and the
inhibition of apoptosis [8]. IGF-1 plays a crucial role
in the regeneration of nitric oxide synthase (NOS) con-
taining nerve fibers in the dorsal and intracavernosal
nerves and administration of IGF-1 can facilitate the
regeneration of NOS containing nerve fibers in penile
tissue and enhance the recovery of erectile function after
bilateral cavernous nerve cryoablation [9, 10]. In diabetic
rats with ED, downregulation of IGF-1 protein expression
was found in penile corpus cavernosum [11].
Because of the wide range of their biologic effects
and therapeutic potential, involvement in a number of
disease processes, the IGF-1 has become the focus of
research by an increasing number of investigators.
The aim of this study was to determine whether any
relationship exists between ED and the level of IGF-1.
Methods
We performed a prospective study of participants who
visited Okmeydani Training and Research Hospital from
March 2011 to January 2013. Before the begining of the
study all patients were evaluated for ED and divided into
two groups: 80 patients suffering from ED for >1 year
and no history of penile surgery or pelvic trauma were
enrolled as a study group and 80 subjects without ED
were enrolled as a control group. Controls are healthy
persons working in the hospital who volunteered for
the study. Local ethics committee approval from
Okmeydani Training and Research Hospital had been
obtained before the commence of the study.
All men had a complete detailed and careful history
taken, with special attention to the sexual history, in-
cluding details to differentiate between psychogenic and
organic ED; a complete physical examination, including
genital and neurological examination; blood glucose assay,
urine analysis, complete blood assessment, and kidney
and liver function; hormonal assays of testosterone, pro-
lactin, and thyroxin; combined intracavernosal injection
and stimulation with a standard dose of 1-mL papaverine
HCl (30 mg). Erectile function was assessed using the
abridged five-item version of the International Index of
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Erectile Function questionnaire (IIEF-5), a validated, self
administered questionnaire. Possible scores for the IIEF-5
range from 5 to 25; scores of 22–25 indicate normal erect-
ile function, while scores of 21 or below indicate ED [12].
According to the IIEF-5 score, ED can be classified as
severe (5–7), moderate (8–11), mild-to-moderate (12–16),
or mild (17–21).
Exclusion criteria included: congestive heart failure
(ejection fraction <50 %), pulmonary hypertension, stroke,
known peripheral atherosclerotic disease, surgical coron-
ary intervention, percutaneous coronary angioplasty and/
or stenting, stable and unstable angina pectoris, impaired
renal function (creatinine > 1.4 mg/dL), unstable endo-
crine or metabolic diseases (e.g., hypoprolactinemia and
hyperprolactinemia, hypoandrogenic and hyperandrogenic
states, hypothyroidism and hyperthyroidism), and patients
with concomitant inflammatory diseases such as infec-
tions and autoimmune disorders, patients with Peyronie
disease acute/chronic hepatic or hepatobiliary disease, and
malignancy. Patients who underwent radical prostatec-
tomy- pelvic surgery, patients with abnormal nutritional
status or eating disorders and taking beta-blocker, spir-
onolactone, corticosteroids, antioxidant vitamins, and
alcohol were also excluded from the study.
Blood samples of all patients were taken from an
antecubital vein following an overnight fasting state.
Serum IGF-1 levels were measured by an Automated
chemiluminescence immunoassay (Immunodiagnostic
Systems Limited, Boldon, Tyne & Wear, UK). Assays for
serum triglyceride (TG), total cholesterol (Total-C), low-
density lipoprotein cholesterol (LDL-C), and high-density
lipoprotein cholesterol (HDL-C) levels were performed in
the hospital’s chemistry laboratory.
Statistical analysis
Statistical analyses were performed by the Statistical
Package for Social Sciences, version 15.0, software (SPSS
Inc., Chicago, IL, USA). The quantitative demographic
values were evaluated by student’s t or Mann Whitney U
test whether the parameters were suitable for normal
distribution or not. If the parameters are qualitative
chi-square test was used. ANOVA test was conducted
to evaluate the difference between subgroups of the
patients stratified for ED. Spearman correlation test
was performed to analyse the association between ED
and IGF-1 level. All tests were performed using a 2-
tailed analysis, and a P value of < 0.05 was considered
statistically significant.
Results
A total of 160 men between the ages of 45 and 70 years
were analysed and divided into the two groups: 80 patients
with ED and 80 subjects without ED (control). The base-
line characteristic properties of study men were
demonstrated in Table 1. The mean age was 60.4 ±
11.3 years in patients with ED group and 55.4 ± 9.63 years
in control group. There were no significant differences be-
tween two groups with respect to age, prevalence of dia-
betes mellitus, hypertension, smoking and levels of fasting
blood glucose, serum creatinine, Total-C, LDL-C, HDL-C,
TG (P > 0.05 for all). The mean value of body mass index
(BMI) in patients with ED was 29.6 ± 3.1 and in con-
trol group was 25.9 ± 2.3. There was statistically dif-
ference for BMI between groups. We compared the
IGF-1 levels between groups. Our results showed that
the patients with ED have lower IGF-1 levels than
control group. Mean IGF-1 level was 96.5 ± 38.3 in
patients with ED and 132.5 ± 53.3 in control goup, re-
spectively. There was statistically difference for IGF-1
levels between the patients with ED and control
group (p < 0.001) (Table 1). The IGF-1 levels were
positively correlated with ED score (r = 0.623, p <
0.01). The IGF-1 levels were significantly decreased
with the grade of ED as mild-to-severe (p < 0.001)
(Fig. 1).
Discussion
The purpose of this investigation was to examine the
association between IGF-1 levels and ED in men. The
results of this study showed that the patients with ED
had significantly lower IGF-1 levels than control group.
Furthermore, our study revealed that there was a posi-
tive correlation between IGF-1 levels and ED score. To







Age (years) 60.4 ± 11.3 55.4 ± 9.6 0.07
Diabetes mellitus (%) 43 36 0.15
Hypertension (%) 37 30 0.20
Smoke (%) 63 57 0.35
Fasting blood glucose (mg/dl) 114.4 ± 35.4 106.7 ± 28.8 0.32
Creatinin (mg/dl) 0.80 ± 0.3 0.77 ± 0.5 0.10
Trigliseride (mg/dl) 191.5 ± 77.8 185.7 ± 71.8 0.40
Total cholesterole (mg/dl) 214.3 ± 23.5 209.6 ± 21.6 0.33
LDL-C (mg/dl) 132.2 ± 18.5 124.3 ± 18.7 0.20
HDL-C (mg/dl) 43.4 ± 10.2 46.9 ± 11.7 0.37
IGF-1 level (ng/ml) 96.5 ± 38.3 132.54 ± 53.3 <0.001*
BMI 29.6 ± 3.1 25.9 ± 2.3 0.001*
ED score 12 ± 1.2 23 ± 0.8 <0.001*
Values are means (±SD) or percentages
BMI Body mass index, ED Erectile dysfunction, HDL-C HIgh-density lipoprotein
cholesterol, LDL-C Low-density lipoprotein cholesterol, IGF-1 Insulin like
growth factor-1
*P < 0.05 was accepted as statistically significant
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our knowledge, this is the first study to show that the
serum levels of IGF-1 represent a marker of ED patients.
This study suggested that IGF-1 might contribute to the
pathophysiology of ED in patients. In a previous study,
IGF-1 levels were lower in diabetic men [13]. In another
study done by Castela A et al. they found that significant
reduction IGF-1 protein expressions in human diabetic
samples [14]. Also, we found that IGF-1 levels were
lower in men with ED; however in our series, DM preva-
lence is similar between men with and without ED. In
this context, IGF-1 levels were lower in men with ED
independently from DM.
ED is caused by two main etiologies: organic and
psychogenic. Organic causes of ED comprise up to 80 %
of cases and vascular disease is the most common
pathophysiology of ED [15]. It was generally accepted
that ED has been associated with advanced atheroscler-
otic disease [16]. IGF-1 suppresses atherosclerosis and
anti-atherosclerotic effect was associated with a reduction
in vascular and systemic oxidative stress, an increase in
circulating nitric oxide (NO) bioavailability and vascular
endothelial nitric oxide synthase (eNOS) expression, the
main NO-producing enzyme in the vascular wall [17].
Also IGF-1 reduced total cell apoptosis in the athero-
sclerotic plaque and increased features of atheroscler-
otic plaque stability [18]. Contrary to its anti-oxidant
effect, antiapoptotic and plaque stability effect of IGF-
1 was NO-independent [12]. But, several other studies
have also reported that endothelial dysfunction in the
penile circulation accompanies ED in association with
various cardiovascular risk factors without advanced
atherosclerotic disease [19, 20].
IGF-I shows high affinities for insulin-like growth fac-
tor binding proteins (IGFBPs). IGFBP-3 carries most of
the circulating IGF-I. IGFBP-3 regulates the availability
of IGF-I by restricting the extravascular transit of IGF-I
to the target cells [21]. It is confirmed that increases in
IGFBP-3 expression due to diabetes would attenuate the
cellular response to IGF-1 through the high affinity bind-
ing of IGF-1 to IGFBP-3. This would result in decreased
availability of IGF-1 for the receptor and may result in ED
[22]. Furthermore, a significant decrease in the amount of
IGF-1 gene expression in penile cavernosum of the dia-
betic rats with ED was confirmed [11]. IGFBP-3 was
detected excess in the penile endothelium and in the
smooth muscle of the corpus cavernosum of the aged rats
and diabetic rats [23]. Both the increased IGFBP-3 and
decreased IGF-1 contributed to decrease the availability of
IGF-1 in erectile tissue and resulting ED.
The corporal cavernosal smooth muscle plays a major
role in modulating penile blood flow during erection
and detumescence [24]. It has been confirmed that erectile
dysfunction is a result of trabecular structural changes,
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Fig. 1 Distributions of IGF-1 levels according to the degree of erectile dysfunction (ED). Values are means (±SD) of IGF-1: 132.5 ± 53.3 [no; n = 80],
125.1 ± 33.2 [mild; n = 29], 98.6 ± 25.1 [mild-moderate; n = 24], 79.6 ± 20.2 [moderate; n = 16] and 41.1 ± 15.3 [severe; n = 11], respectively, p < 0.001
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excess connective tissue accumulation [25]. In a study the
amount of smooth muscle in the corpus cavernosum was
used to evaluate the erectile function. The results show
that IGF- 1 was effective for maintaining the amount of
smooth muscle. The percentage of smooth muscle in the
corpus cavernosum seemed to increase with IGF-1 treat-
ment [26]. It is also suggested that the decrease in IGF-1
is associated with decreased NOS activity and cavernosal
cyclic guanosine monophosphate (cGMP) levels as well as
the decreased smooth muscle integrity, thus impairing
cavernosal smooth muscle relaxation with a resultant
decrease in erectile function [23].
Endothelial dysfunction is characterized by an imbal-
ance between the endothelium-dependent vasodilator
and vasoconstrictor activity, and is associated with a pro-
inflammatory, proliferative, and procoagulatory environ-
ment [27]. Increasing evidence suggests that endothelial
dysfunction is a systemic disorder and implicated in the
pathogenesis of ED, affecting both conduit arteries and
microvessels in various vascular beds [28]. The key role
that regulates endothelial function is endothelial-derived
NO [27]. Endothelial NO is important in producing the
arterial and venous dilation necessary to attain and sustain
an erection. Abnormalities of this vasodilator system are
present in atherosclerosis and play an important role in
the pathophysiology of ED. The penile vascular bed is
dependent on NO for vasodilatation of the arteries to
produce rapid blood inflow and vasodilatation of the
trabecular smooth muscle of the lacunar space to prevent
venous outflow [29]. Dysfunctional endothelial cells lining
the penile arterial system and the corpus cavernosum
produce less NO. Impaired NO activity appears to play a
crucial role in both endothelial dysfunction and ED [30].
IGF-1 has been shown to regulate circulating NO bioavail-
ability and vascular endothelial NOS expression in endo-
thelial cells [31]. IGF-I induces NO-dependent dilation
in the vascular beds. Decreased IGF-1 levels with
aging and diabetes reduce penile NOS expression and
reduced availability of NO are among the causal fac-
tors implicated in ED [32]. IGF-I has roles in cell pro-
liferation, migration, and suppression of apoptosis to
preserve cellular integrity [33]. Endothelial progenitor
cells (EPCs) promote endothelial repair, thereby prevent-
ing endothelial dysfunction [34]. eNOS, which is crucial
for maintenance of endothelial function, is also involved
in mobilization of EPCs from bone marrow. It has been
shown in human subjects that an increase in circulat-
ing IGF-1 or IGF-1 administration raised circulating
EPC numbers and this was associated with increased
NO bioavailability [35].
Part of the allure of IGF-1 as a therapeutic agent is its
wide range of biologic effects and its actions on many
different tissues. Therapeutic effects of IGF-1 on ED
have been studied in animal experiments. Pu et al. [26]
showed that intracavernosal injection of IGF-1 amelio-
rated erectile responses in aged rats. The penile responses
were examined as significant increases in intracavernous
pressure. The erectile responses restored by IGF-1. IGF-1
treatment increased not only the percentage of smooth
muscle, but also increased the expression of eNOS, NOS
activity and cGMP concentration in the penile tissues.
They suggested that the major mechanism underlying
the therapeutic effects of IGF-1 involves increasing
the integrity of smooth muscle and modulating the
NO-cGMP signaling pathways.
The role of oxidative stress has been highlighted in
in vitro studies showing that increased production of
reactive oxygen species is associated with decreased
normal erectile response primarily because of inactiva-
tion of NO [36, 37]. Recent studies suggested that endo-
thelium is a main source of reactive oxygen species
(ROS) [38]. Low IGF-1 serum concentrations were as-
sociated with high oxidative stress in the vasculature,
potentially leading to endothelial dysfunction [39]. IGF-1
reduced superoxides and enhanced expression of antioxi-
dant enzymes such as Mn-superoxide dismutase (SOD),
Cu/Zn-SOD and glutathione peroxidase in animal experi-
mental. The IGF-1-induced antioxidant effect was NO-
dependent (at least in part) since the ability of IGF-1 to
reduce oxidative stress was significantly blunted by L-
arginine methyl ester hydrochloride (L-NAME) [39, 40].
The lack of insulin levels and insulin resistance index
by homeostasis model assessment (HOMA-IR) determi-
nations is a limitation of this study.
Conclusion
This study shows a relationship between decreased serum
IGF-1 level and the presence and severity of ED, which
may be postulated as evidence of endothelial dysfunction
in ED. Serum IGF-1 level might be used in early predic-
tion of ED in future and it may be used in early prediction
of ED in male population. However, further clinical studies
are needed to clarify the pathophysiological role of serum
IGF-1 in ED patients.
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